X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3422) 3422
Publication (514) 514
Book Review (66) 66
Book Chapter (35) 35
Dissertation (10) 10
Conference Proceeding (5) 5
Book / eBook (2) 2
Government Document (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1899) 1899
humans (1607) 1607
animals (1509) 1509
signal transduction (1004) 1004
jak (778) 778
biochemistry & molecular biology (688) 688
cell biology (641) 641
mice (615) 615
phosphorylation (592) 592
jak/stat pathway (561) 561
activation (553) 553
male (521) 521
expression (508) 508
janus kinases - metabolism (465) 465
female (456) 456
immunology (433) 433
oncology (427) 427
stat (413) 413
cytokines (404) 404
signal transduction - drug effects (400) 400
janus kinase (388) 388
apoptosis (379) 379
jak-stat (372) 372
proteins (368) 368
jak/stat (366) 366
stat transcription factors - metabolism (365) 365
jak-stat pathway (351) 351
pharmacology & pharmacy (348) 348
analysis (345) 345
stat3 transcription factor - metabolism (341) 341
inflammation (317) 317
protein-tyrosine kinases - metabolism (310) 310
janus kinase 2 (301) 301
gene expression (300) 300
rats (293) 293
article (289) 289
cell line (288) 288
kinases (285) 285
stat3 (285) 285
signal transduction - physiology (277) 277
cancer (272) 272
cells, cultured (271) 271
gene-expression (269) 269
trans-activators - metabolism (266) 266
dna-binding proteins - metabolism (259) 259
cells (248) 248
jak inhibitor (244) 244
research (241) 241
hematology (237) 237
tofacitinib (232) 232
cell line, tumor (230) 230
receptor (227) 227
janus kinase 2 - metabolism (224) 224
pathway (210) 210
interferon (205) 205
health aspects (203) 203
nf-kappa-b (203) 203
mutation (202) 202
rheumatoid arthritis (201) 201
transcription (201) 201
protein (194) 194
janus kinases - antagonists & inhibitors (190) 190
middle aged (189) 189
proliferation (186) 186
drosophila (183) 183
janus kinase 1 (182) 182
signal-transduction (181) 181
genetic aspects (178) 178
adult (176) 176
cytokine (172) 172
blotting, western (167) 167
cytokines - metabolism (163) 163
jak inhibitors (163) 163
inhibition (161) 161
genes (157) 157
cell proliferation (156) 156
protein kinase inhibitors - pharmacology (153) 153
gene (152) 152
medicine, research & experimental (151) 151
differentiation (149) 149
rheumatology (149) 149
stat1 transcription factor (148) 148
janus kinases - genetics (147) 147
physiological aspects (147) 147
growth (146) 146
transcription factors (146) 146
tyrosine phosphorylation (146) 146
phosphorylation - drug effects (144) 144
proto-oncogene proteins (141) 141
stat1 transcription factor - metabolism (141) 141
stat3 transcription factor (140) 140
apoptosis - drug effects (138) 138
ruxolitinib (137) 137
in-vivo (136) 136
interleukin-6 (136) 136
medicine & public health (136) 136
neurosciences (136) 136
gene expression regulation (135) 135
aged (133) 133
ifn-gamma (133) 133
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3409) 3409
Japanese (20) 20
Chinese (14) 14
German (14) 14
Korean (8) 8
French (7) 7
Portuguese (2) 2
Russian (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 7, pp. 616 - 624
Journal Article
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 05/2016, Volume 75, Issue 5, pp. 831 - 841
ObjectivesTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To further assess the potential role of Janus kinase... 
JAK INHIBITOR | MODIFYING ANTIRHEUMATIC DRUGS | Rheumatoid Arthritis | INADEQUATE RESPONSE | Inflammation | RHEUMATOLOGY | PSORIATIC-ARTHRITIS | LONG-TERM EXTENSION | BACKGROUND METHOTREXATE | FACTOR THERAPY | DMARDs (synthetic) | Treatment | DOUBLE-BLIND | NECROSIS-FACTOR INHIBITORS | SKIN-CANCER | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Incidence | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Young Adult | Clinical Trials, Phase III as Topic | Multicenter Studies as Topic | Neoplasms - chemically induced | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Piperidines - administration & dosage | Administration, Oral | Pyrimidines - administration & dosage | Randomized Controlled Trials as Topic | Protein Kinase Inhibitors - administration & dosage | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Adolescent | Pyrimidines - adverse effects | Aged | Neoplasms - epidemiology | Clinical Trials, Phase II as Topic | Clinical trials | Care and treatment | Usage | Dosage and administration | Tofacitinib | Rheumatoid arthritis | Clinical and Epidemiological Research | 1506
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 4, pp. 745 - 753.e19
Background Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions. Objective Our aim was to... 
Dermatology | dermatology | psoriasis | baricitinib | vitiligo | atopic dermatitis | ruxolitinib | alopecia areata | JAK inhibitors | graft versus host disease | tofacitinib | CONSTITUTIVE ACTIVATION | LUPUS-ERYTHEMATOSUS | T-CELL LYMPHOMA | VERSUS-HOST-DISEASE | LONG-TERM EXTENSION | ALOPECIA-AREATA | JAK1/2 INHIBITOR | CHRONIC PLAQUE PSORIASIS | RANDOMIZED PHASE-III | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Drug Eruptions - etiology | Psoriasis - drug therapy | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Randomized Controlled Trials as Topic | Janus Kinases - antagonists & inhibitors | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Mutual fund industry | Lupus | Psoriasis | Dermatologic agents | Arthritis | Non-Hodgkin's lymphomas | T cells | Rheumatoid factor | Atopic dermatitis | Analysis | Formulae, receipts, prescriptions | Respiratory tract diseases | Skin
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 09/2018, Volume 79, Issue 3, pp. 535 - 544
Janus kinase (JAK) inhibitors have attracted attention for their role in treating inflammatory disorders. This new class of biologics has the potential to... 
topical | JAK-STAT | psoriasis | vitiligo | atopic dermatitis | JAK inhibitor | alopecia areata | EFFICACY | SAFETY | RUXOLITINIB | DERMATOLOGY | ATOPIC-DERMATITIS | JAK1/2 INHIBITOR | CHRONIC PLAQUE PSORIASIS | AUTOIMMUNE-DISEASES | ALOPECIA UNIVERSALIS | TOFACITINIB CITRATE | ALLERGIC DERMATITIS
Journal Article